

Malmö 20 August 2025

PRESS RELEASE

Aptahem files provisional patent application in USA for new indications for Aptahem 1

Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases, today announces that the company has received patent pending status through a provisional patent application in the USA. The application aims to protect the company's lead RNA aptamer Aptahem 1 in new indication areas, based on detailed evaluation of data generated from previous studies with Aptahem 1.

These groundbreaking new insights are based on the detailed evaluation of data generated from Aptahem 1 by the Company's Co-Founder and CSO Dr. Luiza Jedlina. Dr. Jedlina has identified entirely new indications for the Company's lead RNA aptamer, Aptahem 1. These discoveries are now protected by a provisional patent application in the United States, further strengthening Aptahem 1's position as a first-in-class, innovative therapy option.

Some of the identified indications include:

- Neurodegenerative diseases: Aptahem 1 blocks interactions of Amyloid- β and tau, with the potential to slow progression in Alzheimer's, Parkinson's, frontotemporal dementia, and Huntington's disease.
- Viral infections: Effective against HSV, CMV, Dengue, Zika, SARS-CoV-2, MERS, HIV, and HPV by preventing viral cell entry.
- Cancer and metastasis: Inhibits growth factors, slowing angiogenesis and tumor cell spread in aggressive cancers such as breast cancer, melanoma, and glioblastoma.
- Fibrotic diseases and infectious conditions: Interesting indications for idiopathic pulmonary fibrosis, liver and kidney fibrosis, as well as in certain infectious diseases

Dr. Jedlina's evaluation of the study results shows that Aptahem 1 has the potential to stop disease-driving mechanisms at multiple levels – from protein aggregation and pathogen entry to tissue damage and fibrosis – making Aptahem 1 a potential game-changer in these indication areas.

CEO Mikael Lindstam comments:

"Aptahem 1 opens an entirely new frontier in tackling diseases where there are currently no effective therapies. With Dr. Jedlina's discoveries, we are at the cusp of something truly transformative, and it is an exciting moment to be part of Aptahem's journey."

Aptahem is actively engaging with potential partners across these indication areas to fully realize the therapeutic potential of Aptahem 1.

For further information:

Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com

This contains such information that Aptahem AB is obliged to make public according to the EU Market Abuse Regulation. The information was provided through the agency of the above contact person for publication on 20 August 2025.



Malmö 20 August 2025

PRESS RELEASE

About Aptahem

Aptahem AB (APTA) is a clinical stage biotechnology company that develops RNA-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company's lead candidate, Apta-1, is currently in early clinical phase. Apta-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit www.aptahem.com.